Abstract: High affinity aptamer sequences recognizing CD3 protein complex on cell surfaces are provided. The aptamers can be used as targeting moieties for delivery vehicles or as molecular components for immunotherapy, immunodiagnostics, or for isolating, purifying, or characterizing CD3+ T cells in a subject.

Abstract: An aptamer-based switch technology is provided that enhances control of the use of chimeric antigen receptor (CAR)-related immunotherapies. The aptamer-based switch utilizes a synthetic bridge molecule containing a target-binding aptamer bound through a linker to a CAR-binding aptamer. A system containing a CAR and a corresponding aptameric bridge provides an immunotherapy platform that: (i) can be targeted to any desired antigen by choosing the target-binding aptamer of the bridge. (ii) can be redirected from one target to another by changing the target-binding aptamer: (iii) can be dosed according to the changing needs of an individual patient overtime by altering the administration protocol for the bridge: (iv) can be switched on or off quickly or gradually: (v) can be used as a companion diagnostic for a specific CAR therapy: (vi) can be integrated with either in vivo or ex vivo CAR expression: (vii) is non-immunogenic; and (viii) has low production costs.

Abstract: Engineered multispecific antigen binding molecules are provided which contain two or more different aptamer moieties joined by a linker. The antigen binding molecules are capable of specifically binding to one or more antigens and bridging different cell types, such as immune cells and cancer cells. The linked aptamers can be used to modulate and enhance immune function.

Abstract: High affinity aptamer sequences recognizing CD3 protein complex on cell surfaces are provided. The aptamers can be used as targeting moieties for delivery vehicles or as molecular components for immunotherapy, immunodiagnostics, or for isolating, purifying, or characterizing CD3+ T cells in a subject.

Abstract: An aptamer-based switch technology is provided that enhances control of the use of chimeric antigen receptor (CAR)-related immunotherapies. The aptamer-based switch utilizes a synthetic bridge molecule containing a target-binding aptamer bound through a linker to a CAR-binding aptamer. A system containing a CAR and a corresponding aptameric bridge provides an immunotherapy platform that: (i) can be targeted to any desired antigen by choosing the target-binding aptamer of the bridge, (ii) can be redirected from one target to another by changing the target-binding aptamer; (iii) can be dosed according to the changing needs of an individual patient overtime by altering the administration protocol for the bridge; (iv) can be switched on or off quickly or gradually; (v) can be used as a companion diagnostic for a specific CAR therapy; (vi) can be integrated with either in vivo or ex vivo CAR expression; (vii) is non-immunogenic; and (viii) has low production costs.

Abstract: A system for “signal-on” electrochemical detection of molecules of interest and to a method implementing said system.

Abstract: A system for “signal-on” electrochemical detection of molecules of interest and to a method implementing said system.